Human Oncology & Pathogenesis Program
The Piro Lito Lab
Our group studies the properties of oncoproteins that drive cancer cell growth, focusing on lung cancer and other solid tumors. We are interested in understanding how these are activated, their regulatory mechanisms, and how they modulate the behavior of cancer cells. To answer these questions we utilize small molecule inhibitors coupled with biochemical and genetic approaches in patient-derived cell line or xenograft model systems. We aim to provide insight into the fundamental processes that govern tumor biology and to identify therapeutic interventions that will prolong survival and improve the quality of life in patients with cancer.
Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L, Risso D, Lito P. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577(7790):421-5. doi: 10.1038/s41586-019-1884-x. PMID: 31915379
Hong DS*, Fakih MG, Strickler JH, Desai J, Durm JA,Shapiro GI, Falchook GS, Price TJ, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Lito P*, Govindan R*, Li BT*. KRAS G12C inhibition in advanced solid tumors. New England Journal of Medicine, 2020. Sep 24;383(13):1207-1217. PMID: 32955176* Equal contribution/co-senior authors
Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P. An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer. Nature Medicine. 2017;23(8):929-37. doi: 10.1038/nm.4369. PMID: 28714990
Piro Lito, MD, PhD
- Physician-scientist Piro Lito studies oncoproteins that drive cancer cell growth.
- MD,PhD, Michigan State University
- View physician profile
- Physician profile
- Josie Robertson Investigator (2016-2021)
- Pew-Stewart Scholar for Cancer Research (2019)
- Damon Runyon Clinical Investigator (2017)
- The V Foundation for Cancer Research, Translational Research Award (2015)
- LUNGevity Foundation, Career Development Award (2015)
- NIH K08, Mentored Clinical Scientist Research Career Development Award (2015)
- Stand up to Cancer Lung Cancer Dream Team, Young Investigator (2015)
- Conquer Cancer Foundation, Young Investigator Award (2013)
- Charles A. Dana Fellow/Clinical Scholar in Biomedical Research (2011)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Piro Lito discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.